Abstract
Three human cases of H10N8 viruses were reported in China in late 2013 and early 2014, two of which were fatal. This was the first time the H10N8 subtype has been detected in humans and no vaccine candidates or antibody therapy has been developed for these viruses so far. We developed an H10N8 vaccine candidate virus based on A/Jiangxi-Donghu/346/13 that can also be used in a murine challenge model for vaccine and monoclonal antibody research. The vaccine virus is a 6:2 re-assortant virus expressing the surface glycoproteins of A/Jiangxi-Donghu/346/13 on an A/Puerto Rico/8/34 backbone. Vaccination with inactivated challenge virus or recombinant hemagglutinin or neuraminidase derived from this strain protected mice from viral challenge.
Original language | English |
---|---|
Pages (from-to) | 1102-1106 |
Number of pages | 5 |
Journal | Vaccine |
Volume | 33 |
Issue number | 9 |
DOIs | |
State | Published - 25 Feb 2015 |
Keywords
- Avian influenza
- Emerging viruses
- H10N7, Influenza vaccine
- H10N8
- Influenza virus